Compare NREF & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NREF | LXEO |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.0M | 348.7M |
| IPO Year | N/A | 2023 |
| Metric | NREF | LXEO |
|---|---|---|
| Price | $11.24 | $3.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $14.50 | ★ $20.67 |
| AVG Volume (30 Days) | 66.3K | ★ 1.1M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | ★ 16.30% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.16 | $2.55 |
| 52 Week High | $18.43 | $10.99 |
| Indicator | NREF | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 20.74 | 54.64 |
| Support Level | N/A | $2.72 |
| Resistance Level | $16.04 | $3.56 |
| Average True Range (ATR) | 0.68 | 0.38 |
| MACD | -0.27 | 0.05 |
| Stochastic Oscillator | 2.47 | 36.56 |
NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.